ArticleJournal of personalized medicine2022
Neuro-Oncology Multidisciplinary Tumor Board: The Point of View of the Neuroradiologist.
Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Transforming Brain Tumor Care: The Global Impact of Radiosurgery in Multidisciplinary Treatment Over Two Decades.Cancer medicine · 2025Pooled it
- SEOM-GEINO clinical guidelines for grade 2 gliomas (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Impact of holiday periods on glioblastoma surgery: a Dutch nationwide population-based cohort study.Scientific reports · 2026Article
- Current landscape and challenges of neuro-oncological molecular tumor boards in Germany: results of a nationwide follow-up survey.Journal of neuro-oncology · 2026Article
- Timing Matters: Optimizing Oncology Involvement in Pediatric Neuro-Oncology Pathways in Saudi Arabia.Neurosciences (Riyadh, Saudi Arabia) · 2026Article
- One-year follow-up of the new European reference network for pediatric cancers (ERN PaedCan) tumor board for pediatric CNS tumors: lessons learnt and future prospects.Journal of neuro-oncology · 2025Article
- Multidisciplinary, Clinical Assessment of Accelerated Deep-Learning MRI Protocols at 1.5 T and 3 T After Intracranial Tumor Surgery and Their Influence on Residual Tumor Perception.Diagnostics (Basel, Switzerland) · 2025Article
- Role of the tumor board when prescribing mutant isocitrate dehydrogenase inhibitors to patients with isocitrate dehydrogenase-mutant glioma.Neuro-oncology practice · 2025Review
- The initiation of the second-step intradisciplinary tumor board discussion and its impact on treatment decision. Retrospective data analysis of 12 years' experience in a tertiary oncology center.Frontiers in oncology · 2025Article
- Multidisciplinary quantitative and qualitative assessment of IDH-mutant gliomas with full diagnostic deep learning image reconstruction.European journal of radiology open · 2024Article
- Central nervous system pediatric multi-disciplinary tumor board: a single center experience.BMC cancer · 2024Article
- Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors.Journal of neuro-oncology · 2024Article
- Insights into Healthcare Professionals' Perceptions and Attitudes toward Nanotechnological Device Application: What Is the Current Situation in Glioblastoma Research?Biomedicines · 2023Review
- Building Team Medicine in the Management of CNS Metastases.Journal of clinical medicine · 2023Article
- Development of an enhanced recovery protocol after laser ablation surgery protocol: a preliminary analysis.Neuro-oncology practice · 2023Article
- Neurosurgical Defeats: Critically Ill Patients and the Role of Palliative Care Service.Journal of personalized medicine · 2022Article
- Article
- Sub-regional networking in neuro-oncology: Towards a West African collaborative platform.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe multi-disciplinary tumor board (MTB) is essential to quality cancer care and currently recommended to offer the best personalized clinical approach, but little has been published regarding MTBs in neuro-oncology (nMTBs). The aim of the present paper is to describe our nMTB, to evaluate its impact on clinical management decisions, and to assess the role of neuroradiologists.
methodsThe retrospective evaluation of the cases discussed at our nMTB from March 2017 to March 2020. From the electronic records, we extracted epidemiological, clinical and other specific data of nMTB. From the radiological records, we calculated data relating to the number, time for revision, and other specifications of MRI re-evaluation. Statistical analysis was performed.
resultsa total of 447 discussions were analyzed, representing 342 patients. The requests for case evaluations came from radiation oncologists (58.8%) and neurosurgeons (40.5%), and were mainly addressed to the neuroradiologist (73.8%). The most frequent questions were about the treatment's changes (64.4%). The change in patient treatment was reported in 40.5% of cases, 76.8% of these were based on the neuroradiologic assessment. A total of 1514 MRI examinations were re-evaluated, employing approximately 67 h overall. The median of the MRI exams reviewed per patient was 3 (min-max 1-12).
conclusionsOur study supported that the multidisciplinary approach to patient care can be particularly effective in managing brain tumors. A review by an expert neuroradiologist impacts patient management in the context of nMTBs, but has costs in terms of the time and effort spent preparing for it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.